A new tumor suppressor role for the Notch pathway in bladder cancer

Nature Medicine

Volumn 20, Issue 10, 2014, Pages 1199-1205

  Rampias, Theodoros ^a   Vgenopoulou, Paraskevi ^a   Avgeris, Margaritis ^b   Polyzos, Alexander ^a   Stravodimos, Konstantinos ^b   Valavanis, Christos ^c   Scorilas, Andreas ^b   Klinakis, Apostolos ^a  

^a Academy of Athens Biomedical Research Foundation   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; JAGGED1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH RECEPTOR; RAS PROTEIN; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UNITED STATES; UPREGULATION; ANIMAL; BLADDER TUMOR; DEFICIENCY; DISEASE MODEL; GENE DOSAGE; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; GENE DOSAGE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; RECEPTOR, NOTCH1; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84921973696     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3678     Document Type: Article

References (35)

1. Artavanis-Tsakonas, S., Rand, M. D., Lake, R. J. Notch signaling: cell fate control and signal integration in development. Science 284, 770-776 (1999).
2. Lobry, C., Oh, P., Aifantis, I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J. Exp. Med. 208, 1931-1935 (2011).
3. Jemal, A., Siegel, R., Xu, J., Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
4. Cordon-Cardo, C. Molecular alterations associated with bladder cancer initiation and progression. Scand. J. Urol. Nephrol. Suppl. 154-165 (2008).
5. Knowles, M. A. Molecular pathogenesis of bladder cancer. Int. J. Clin. Oncol. 13, 287-297 (2008).
6. Nicolas, M. et al. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33, 416-421 (2003).
7. Lefort, K. et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK kinases. Genes Dev. 21, 562-577 (2007).
8. Klinakis, A. et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473, 230-233 (2011).
9. Wang, N. J. et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 108, 17761-17766 (2011).
10. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
11. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
12. Jerez, A. et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J. Clin. Oncol. 30, 1343-1349 (2012).
13. Kimura, F. et al. Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br. J. Cancer 85, 1887-1893 (2001).
14. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
15. Funahashi, Y. et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 68, 4727-4735 (2008).
16. Cancer Genome Atlas Research. N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
17. Guo, G. et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 45, 1459-1463 (2013).
18. Iyer, G. et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 31, 3133-3140 (2013).
19. Cazier, J. B. et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat. Commun. 5, 3756 (2014).
20. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
21. Weng, A. P. et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol. Cell. Biol. 23, 655-664 (2003).
22. Maraver, A. et al. Therapeutic effect of ?-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 22, 222-234 (2012).
23. Yu, H. M., Liu, B., Chiu, S. Y., Costantini, F., Hsu, W. Development of a unique system for spatiotemporal and lineage-specific gene expression in mice. Proc. Natl. Acad. Sci. USA 102, 8615-8620 (2005).
24. Perl, A. K., Wert, S. E., Nagy, A., Lobe, C. G., Whitsett, J. A. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc. Natl. Acad. Sci. USA 99, 10482-10487 (2002).
25. Karni-Schmidt, O. et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am. J. Pathol. 178, 1350-1360 (2011).
26. Shin, K. et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat. Cell Biol. 16, 469-478 (2014).
27. Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152-165 (2014).
28. Ho, P. L., Kurtova, A., Chan, K. S. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat. Rev. Urol. 9, 583-594 (2012).
29. Buonamici, S. et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459, 1000-1004 (2009).
30. Dotto, G. P. Crosstalk of Notch with p53 and p63 in cancer growth control. Nat. Rev. Cancer 9, 587-595 (2009).
31. Han, H. et al. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int. Immunol. 14, 637-645 (2002).
32. Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611 (2009).
33. Ahmad, I. et al. K-Ras and ?-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis. Model. Mech. 4, 548-555 (2011).
34. Zhou, H. et al. Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis 33, 770-780 (2012).
35. Livak, K. J., Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2C(T) method. Methods 25, 402-408 (2001).